You need to create a user account to read this article.
With a subscription you unlock more content on BioStock.
Guard Therapeutics rages after missed targets
Text:
Kim Liedholm | [email protected]
Guard Therapeutics presents topline results from the Phase IIb POINTER clinical trial with the lead candidate RMC-035 to prevent acute kidney injury in patients undergoing cardiac surgery. The trial met neither its primary endpoint...